Author

M. Lehner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Benjak· 1 shared A. Bykov· 1 shared A. Dupanovic· 1 shared A. King-Yung Leung· 1 shared A. Naveed· 1 shared A. Plach· 1 shared A. R. Poetsch· 1 shared B. Daniel· 1 shared

Activity by Year

2023-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Benjak

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader molecules

P. D. Thienger, I. Paassen, X. Yao, P. D. Rubin, M. Lehner, N. Lillis, A. Benjak, S. Shah, A. King-Yung Leung, S. de Brot, A. Naveed, B. Daniel, M. Shi, J. Tremblay, J. Triscott, , M. A. Rubin

This study identifies a SWI/SNF-targeting therapy effective against a double-negative prostate cancer subtype, showing it reduces viability in both AR-dependent and WNT-dependent models.

bioRxiv · Mar 24, 2024Cancer Biology

Natural killer cell cytotoxicity shapes the clonal evolution of B cell leukaemia

M. C. Buri, M. R. Shoeb, A. Bykov, P. Repiscak, H. Baik, A. Dupanovic, F. O. David, B. Kovacic, F. Hall-Glenn, S. Dopa, J. Urbanus, L. Sippl, S. Stofner, D. Emminger, J. Cosgrove, , E. M. Putz

This study shows NK cells influence all phases of cancer immunoediting in B-ALL, promoting resistant clones through selective pressure and identifying LY6E as a marker of poor prognosis.

bioRxiv · Nov 16, 2023Cancer Biology

TCR/CD3-based synthetic antigen receptors (TCC) convey superior antigen sensitivity combined with high fidelity of activation

T. Peters, V. Muehlgrabner, R. M. H. Velasco Cardenas, R. Platzer, J. Gohring, B. Salzer, A. Plach, M. Hoehrhan, I. Doel-Perez, V. D. R. Goncalves, J. S. Farfan, M. Lehner, H. Stockinger, W. W. Schamel, K. Schober, , J. B. Huppa

This study shows TCR/CD3-based synthetic antigen receptors (TCC) have superior antigen sensitivity and activation fidelity compared to second-generation CARs.

bioRxiv · Mar 16, 2023 · PreprintImmunology